A Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes Mellitus and End-Stage Renal Disease Who Are on Dialysis and Who Have Inadequate Glycemic Control. - MK-431-073
Latest Information Update: 09 May 2022
At a glance
- Drugs Glipizide (Primary) ; Sitagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 18 Mar 2013 New source identified and integrated (Clinical Trials Registry - India record: CTRI2009-091-000140).
- 27 Apr 2011 Actual end date (1 Mar 2011) added as reported by ClinicalTrials.gov.
- 27 Apr 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.